We would like to thank our partners and sponsors for supporting us and the whole event, our speakers and advisers for contributing with their knowledge, experience and strategies, and all delegates for finding the time to join us in Barcelona. We are delighted that you chose to attend the 2nd Annual World Orphan Drug Congress and we had the chance to meet you there and talk to you.
If you have any further questions or you are just eager to learn more about our upcoming events, do not hesitate to contact us. We would also appreciate your comments and suggestions that could help us improve our future conferences.
When orphan drugs are still at the early stages of development,the latest and most accurate information is required for the drug to advance efficiently.
Fleming Europe organizes the 2nd Annual Orphan Drug Congress 2012,
where worldwide pharmaceutical experts will share their experiences and insight.
KEY TOPICS
- Successful development plan for Orphan Drug
- Regulatory challenges surrounding Orphan drug development
- Developing patient registries
- Commercial aspects of orphan drug development
- Patient perspective
+ PLUS
- Ms Sharon Terry (President and CEO of Genetic Alliance) will open the first day of the conference with keynote presentation “A team of teams: Orphan drug development”
- President of OrphaNet Ms Segolene Ayme will present International Rare Disease Research Initiative
Development of orphan and ultra orphan drugs to prevent, diagnose and treat rare diseases is very challenging dueto its niche nature. On the other hand, rare diseases show the potential of less intense competition, faster and less expensive development, and lower marketing spend on a small, highly motivated audience.
FIND YOUR REASONS TO ATTEND
- Understand the infrastructure in order to gain approval in emerging markets
- Gain critical insights behind the successful development, authorization and reimbursement of rare disease drugs
- Find out how to regulate the use of social media for orphan drugs & rare diseases
- Explore the importance of communication Between Pharma, Patient & HTA Bodies
- Top executives and experts coming from leading pharmaceutical companies as well as from medium and small pharma companies with the focus on rare and neglected diseases:
BIG PHARMA: Genzyme, Pfizer, Sanofi Aventis, Celgene, Ipsen, Actellion, Bayer, Merck Serono, Amgen, Shire
S&M SPECIALIZED COMPANIES: Swedish Oprhan Biovitrum, HRA Pharma, BioMarin, Orphan France, Alexion
Plus: President of OrphaNet, Expert patient and Professor from University of Edinburgh, HTA representatives and Ministries coming from the key western European markets UK, Germany, France, Spain and Switzerland
ENDORSING PARTNERS
 |
 |
 |
 |
Contact us
"Hi, I am Ivana. Do you have any questions regarding this conference? Do not hesitate to contact me."
Last year's conference
Watch our speakers talking about past year event.
Venue confirmed
Hotel Avenida Palace
